Home › NCT05046080

Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix

Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix - a Rare Tumor

Who can join

All ages · Women

Inclusion Criteria:

* Patients diagnosed with clear cell carcinoma of the cervix at MDACC

About the study

This study aims to provide a comprehensive report on clinicopathologic features, immunohistochemical/biomarker testing and molecular profile of cervical clear cell carcinoma. This study may help researchers learn more about the molecular profile of cervical clear cell carcinoma.

What is being tested

• Electronic Health Record Review (other)
• Laboratory Biomarker Analysis (other)

Sponsor: M.D. Anderson Cancer Center · Participants: 70 · Started: Aug 6, 2021

Contact the study team

Official record on ClinicalTrials.gov — NCT05046080

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.